Verubecestat - Ligand Pharmaceuticals/Merck & Co

Drug Profile

Verubecestat - Ligand Pharmaceuticals/Merck & Co

Alternative Names: MK-8931; SCH-900931

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antidementias; Fluorobenzenes; Pyridines; Small molecules; Thiadiazines
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 13 Feb 2018 Merck terminates the phase III EPOCH trial in Alzheimer's disease in Norway, Switzerland, Spain, Netherlands, Germany, Italy, France, Finland, Austria, Belgium, United Kingdom, South Korea, Japan, New Zealand, Australia, Canada, USA (PO) (NCT01953601)
  • 16 Jul 2017 Pharmacodynamics data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 12 Apr 2017 Merck Sharp & Dohme completes a two-part phase I pharmacokinetics trial in USA (PO, Tablet) (NCT02910739)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top